Stay updated with breaking news from Solid Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Global Gene Therapies For Rare Diseases market is expected to reach US$ 11,441.6 Million by 2030, with a CAGR of 21.7% during a forecast period of 2022-2030.
Otherwise they might end up a niche treatment for a small number of patients in rich countries | Briefing
Here is how late-stage gene therapy programs offer a glimpse into the future of rare disease medicine.
Private equity firm KKR teamed up with OMX Ventures to lead the seed investment in Replay, a company developing a suite of technologies that could overcome capacity limitations of adeno-associated viruses used for genetic medicines delivery. Duchenne muscular dystrophy is among the disease targets of the new startup.
/PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated...